Molecular-Driven Treatment Advances in HER2+ Metastatic Colorectal Cancer

Molecular-Driven Treatment Advances in HER2+ Metastatic Colorectal Cancer

ReachMD Healthcare Image

Are you aware of the changing landscape surrounding the treatment of HER2-positive metastatic colorectal cancer?  Our experts have the latest data.

Available credits: 0.25

Time to complete: 15 minutes


Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Are you familiar with the most recent clinical data surrounding the treatment of HER2-positive metastatic colorectal cancer?  Listen in as Drs. Tanios Bekii-Saab and Joleen Hubbard talk about the recent approval of tucatinib and trastuzumab for the treatment of HER2-positive metastatic CRC and other therapies in development.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Tanios S. Bekaii-Saab, MD
    Professor of Medicine
    Leader, Gastrointestinal Cancer Program
    Mayo Clinic Cancer Center
    Scottsdale, AZ

    Consulting Fees: BioNTech, Celldex Therapeutics, GSK, Kura Oncology, Merck, Pfizer, Vaccinex
    Contracted Research: BMS, Exelixis

    Joleen M. Hubbard, MD
    Associate Professor of Medical Oncology
    Mayo Clinic
    Rochester, MN

    Consulting Fees: Boehringer Ingelheim, Genentech

    Reviewers/Content Planners/Authors:

    • Jorge Bacigalupo, PSM has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Rosanne Strauss, PharmD, MBA has nothing to disclose.
  • Learning Objectives

    Learning Objectives After participating in this educational activity, participants should be better able to:

    • Identify appropriate testing to personalize treatment for patients with HER2+ metastatic colorectal cancer (mCRC)
    • Summarize clinical data of existing and emerging treatment options for patients with HER2+ mCRC
  • Target Audience

    This activity is designed to meet the educational needs of medical oncologists, pathologists, gastroenterologists and other oncology HCPs treating patients with CRC.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.

  • Commercial Support

    This activity is supported by an independent educational grant from Seagen Inc.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments


We’re glad to see you’re enjoying Prova Education…
but how about a more personalized experience?

Register for free